BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36871674)

  • 1. Slow skeletal muscle troponin T acts as a potential prognostic biomarker and therapeutic target for hepatocellular carcinoma.
    Huang SC; Huang CC; Ko CY; Huang CY; Liu CH; Lee YK; Chen TY; Hsueh CW; Tzou SJ; Tai MH; Hu TH; Tsai MC; Lee WC; Ho YC; Wu CC; Chang YC; Chang JJ; Liu KH; Li CC; Wen ZH; Chang CL; Chu TH
    Gene; 2023 May; 865():147331. PubMed ID: 36871674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNNT1, a prognostic indicator in colon adenocarcinoma, regulates cell behaviors and mediates EMT process.
    Hao YH; Yu SY; Tu RS; Cai YQ
    Biosci Biotechnol Biochem; 2020 Jan; 84(1):111-117. PubMed ID: 31512553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-370 Regulates Cellepithelial-Mesenchymal Transition, Migration, Invasion, and Prognosis of Hepatocellular Carcinoma by Targeting GUCD1.
    He Y; He X
    Yonsei Med J; 2019 Mar; 60(3):267-276. PubMed ID: 30799589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
    J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-3607, a biomarker of hepatocellular carcinoma invasion and aggressiveness: Its relationship with epithelial-mesenchymal transition process.
    Hu WY; Wei HY; Liu LY; Li KM; Wang RB; Xu XQ; Feng R
    IUBMB Life; 2020 Aug; 72(8):1686-1697. PubMed ID: 32311821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma.
    Chen K; Li Z; Zhang M; Wang B; Peng T; Shen Y; Zhang J; Ye J; Liu Y; Tang D; Peng M; Ma D; Xiao Z; Zhang Y; Jin W; Li X
    Biomed Res Int; 2020; 2020():1964219. PubMed ID: 33083453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
    J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
    Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
    Li D; Zhang Y; Zhang H; Zhan C; Li X; Ba T; Qiu Z; E F; Lv G; Zou C; Wang C; Si L; Zou C; Li Q; Gao X
    J Exp Clin Cancer Res; 2018 Mar; 37(1):46. PubMed ID: 29506532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
    Jin Y; Wang J; Han J; Luo D; Sun Z
    Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma.
    Yang Y; Liu Q; Li Z; Zhang R; Jia C; Yang Z; Zhao H; Ya S; Mao R; Ailijiang T; Bao Y; Zhang H
    Carcinogenesis; 2018 Jul; 39(7):900-910. PubMed ID: 29365054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical relevance of epithelial-mesenchymal transition and its correlations with tumorigenic immune infiltrates in hepatocellular carcinoma.
    Qiu ZQ; Wang X; Ji XW; Jiang FJ; Han XY; Zhang WL; An YH
    Immunology; 2022 Jun; 166(2):185-196. PubMed ID: 35274290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA AK021443 Promotes Cell Proliferation and Migration by Regulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
    Yang J; Li J; Liu B; Zhang R; Gu F; Zhao J; Cheng S
    DNA Cell Biol; 2018 May; 37(5):481-490. PubMed ID: 29638164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
    Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
    Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFκB pathway in hepatocellular carcinoma.
    Chang H; Li J; Qu K; Wan Y; Liu S; Zheng W; Zhang Z; Liu C
    Cell Death Dis; 2020 May; 11(5):332. PubMed ID: 32382077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
    Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
    Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
    EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.